StockData
GNLXNasdaqPharmaceutical PreparationsFiscal year ends December 31

GENELUX Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.45+0.03 (+1.24%)

Close on Oct 19, 2026

Market cap
$110.15M
P/E (TTM)
–
Dividend yield
–

Earnings

Quarterly results announced on Form 8-K, Item 2.02

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q4 FY2024
Ended Dec 31, 2024
Mar 25, 2025Before market open–––
Q4 FY2023
Ended Dec 31, 2023
Feb 2, 2024During market hours–––

Press releases

Announcements Genelux filed with the SEC